DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for allergic contact dermatitis — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAllergic contact dermatitis maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for allergic contact dermatitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glycogenin 1 (GYG1) — GYG1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet g6pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7Q13 · 3.0 Å · ligand 6-O-phosphono-alpha-D-glucopyranose (G6P). Experimental structure, not a prediction.
What the evidence adds up to
Allergic contact dermatitis accounts for up to 7% of all dermatologic consultations in the United States. The disease involves two distinct phases: induction (sensitisation) and elicitation. Patients who see a doctor are already sensitised, so further work on the elicitation phase is needed to improve prevention and treatment. Several key molecules — including cytokines and adhesion molecules — have been identified, and attempts are being made to develop more specific pharmacologic and immunologic inhibitors of their activity. No such inhibitor has been tested in a controlled trial reported in these abstracts.
The incidence of allergic contact dermatitis appears to be lower in patients with atopic dermatitis than in patients with other forms of dermatitis, but a significant number of atopics still show positive patch test reactions. Patch testing is a useful clinical tool, but its limitations must be kept in mind. The evaluation of any eczematous dermatosis should consider contact reactions as potential contributing factors.
No concrete numbers — survival, response rates, or sample sizes — are given in any of these abstracts. No drug is named, tested, or proposed for repurposing. The abstracts are reviews and opinion pieces, not original trial reports.
What is still missing is any clinical trial data that tests a specific molecular inhibitor in patients with allergic contact dermatitis. Also absent is a clear strategy for patient stratification — for example, separating atopic from non-atopic individuals — and the funding needed to run such trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatologic Therapy · 2004 · 40 citations
Allergic contact dermatitis: pathophysiology applied to future therapy
AbstractContact dermatitis is a common reason for patient visits to primary-care clinics and represents up to 7% of all dermatologic consultations in the US. Substantial progress has been made in elucidating the pathophysiology of contact dermatitis, particularly the allergic form. A better understanding of pathologic mechanisms has led to improved management of cases and will continue to advance treatment modalities. The present paper reviews the pathogenesis and current treatment of allergic contact dermatitis and speculates on the prospects for improved future therapy.
American Journal of Contact Dermatitis · 2000 · 22 citations
Sensitization versus elicitation in allergic contact dermatitis: Potential differences at cellular and molecular levels
AbstractThe induction and elicitation phases of allergic contact dermatitis are very complicated processes that differ in many respects. Many issues remain to be investigated, especially in the elicitation phase of this disease. Several key molecules involved in the development and maintenance of allergic contact dermatitis have already been defined, including a number of different cytokines and adhesion molecules. Attempts are being made to develop new, more specific pharmacologic and immunologic inhibitors of their activity. Because patients who see a doctor are already sensitized, further elucidation of the factors affecting the elicitation of allergic contact dermatitis will greatly contribute to the prevention and treatment of the disease.
Dermatologic Clinics · 1994 · 17 citations · open access
Should Atopic Individuals be Patch Tested?
AbstractAlthough it appears that the incidence of allergic contact dermatitis is lower in patients with atopic dermatitis than in patients with other forms of dermatitis, studies have shown that a significant number of atopics demonstrate allergic contact dermatitis on testing. This article presents a review of the larger studies that have been performed in atopic individuals as well as recommendations for patch testing.
American Journal of Contact Dermatitis · 1994 · 12 citations
Controversies in Contact Dermatitis
AbstractBackground: To the clinical dermatologist caring for patients with eczematous dermatoses, questions about the scope and effective evaluation of contact dermatitis often arise. Objective: This editorial review summarizes the author's opinions about some commonly arising controversies in contact dermatitis. Methods: the pros and cons of the issues under discussion are presented and supported by personal experience and literature references. Results / Conclusions: The evaluation of a patient with an eczematous dermatosis should consider the broad scope of contact reactions as potential contributing factors. Patch testing, used with a realistic perspective of the technique's limitations, is a useful clinical tool in the diagnosis of allergic contact dermatitis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
